Out to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player

Amber Tong

Frank Nestle was appointed Sanofi’s global head of immunology and inflammation research therapeutic area just days before dupilumab, the blockbuster-to-be IL-4 antibody, would be accepted …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Out to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Rare disease biopharma companies weigh in on FDA's new innovation hub

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Out to re­vive R&D, a resur­gent Sanofi pays $150M cash to part­ner up with a pi­o­neer­ing pro­tein degra­da­tion play­er

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Out to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player